Battling Acute Myeloid Leukemia (AML) as both a Clinician and Scientist
Acute myeloid leukemia (AML) is characterized by the accumulation of immature hematopoietic cells in the bone marrow that impair normal blood formation. Chemotherapy is always the first treatment option for AML. Patients can also be cured by allogeneic stem cell transplantation, which consists of transferring stem cells from a healthy donor to the patient after high-intensity (high-dose) chemotherapy. Many mutations found in AML affect the cells on an epigenetic level, influencing the gene expression of the cells such as influencing DNA-methylation genes and chromatin-modifying genes. Affecting these epigenetic mechanisms is therefore of great interest in the area of AML.
How to Cite
Authors submitting to the journal must adhere to the terms of Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license as outlined below:
1. You are free to share (copy and redistribute) any material from this journal, granted you have given appropriate credit, provided the link to the license, and indicated whether changes were applied to original work.
2. You are free to adapt (remix, transform, and build upon) any material from this journal, granted you distribute your work under the same license.